Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 4
2019 6
2020 6
2021 8
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
Khan HY, Nagasaka M, Aboukameel A, Alkhalili O, Uddin MH, Bannoura SF, Mzannar Y, Azar I, Beal EW, Tobon ME, Kim SH, Beydoun R, Baloglu E, Senapedis W, El-Rayes BF, Philip PA, Mohammad RM, Shields AF, Al Hallak MN, Azmi AS. Khan HY, et al. Mol Cancer Ther. 2023 Dec 1;22(12):1422-1433. doi: 10.1158/1535-7163.MCT-23-0251. Mol Cancer Ther. 2023. PMID: 37703579 Free PMC article.
Clinical progress of KRAS-targeted therapies: what next?
Nagasaka M, Azmi AS. Nagasaka M, et al. Future Med Chem. 2022 Aug;14(15):1107-1110. doi: 10.4155/fmc-2022-0128. Epub 2022 Jun 27. Future Med Chem. 2022. PMID: 35758004 No abstract available.
Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
Khan HY, Nagasaka M, Li Y, Aboukameel A, Uddin MH, Sexton R, Bannoura S, Mzannar Y, Al-Hallak MN, Kim S, Beydoun R, Landesman Y, Mamdani H, Uprety D, Philip PA, Mohammad RM, Shields AF, Azmi AS. Khan HY, et al. Cancer Res Commun. 2022 May;2(5):342-352. doi: 10.1158/2767-9764.crc-21-0176. Epub 2022 May 10. Cancer Res Commun. 2022. PMID: 35573474 Free PMC article.
Connecting the Human Microbiome and Pancreatic Cancer.
Sexton RE, Uddin MH, Bannoura S, Khan HY, Mzannar Y, Li Y, Aboukameel A, Al-Hallak MN, Al-Share B, Mohamed A, Nagasaka M, El-Rayes B, Azmi AS. Sexton RE, et al. Cancer Metastasis Rev. 2022 Jun;41(2):317-331. doi: 10.1007/s10555-022-10022-w. Epub 2022 Apr 2. Cancer Metastasis Rev. 2022. PMID: 35366155 Free PMC article. Review.
Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology.
Hall WA, Kamgar M, Erickson BA, Ponce SB, Tsai S, Nevalainen MT, Christians KK, George B, Dua KS, Khan AH, Evans DB, Azmi AS. Hall WA, et al. Cancer Metastasis Rev. 2021 Sep;40(3):879-889. doi: 10.1007/s10555-021-09993-z. Epub 2021 Oct 6. Cancer Metastasis Rev. 2021. PMID: 34611794 Free PMC article. Review.
Targeting KRAS in pancreatic cancer: new drugs on the horizon.
Bannoura SF, Uddin MH, Nagasaka M, Fazili F, Al-Hallak MN, Philip PA, El-Rayes B, Azmi AS. Bannoura SF, et al. Cancer Metastasis Rev. 2021 Sep;40(3):819-835. doi: 10.1007/s10555-021-09990-2. Epub 2021 Sep 9. Cancer Metastasis Rev. 2021. PMID: 34499267 Free PMC article. Review.
28 results